Cargando…
Pleural LDH as a prognostic marker in adenocarcinoma lung with malignant pleural effusion
To study the performance of serum and pleural lactate dehydrogenase (LDH) level in predicting survival in patients with adenocarcinoma lung presenting with malignant pleural effusions (MPE) at initial diagnosis. Retrospective cohort study of the patient hospitalized for adenocarcinoma lung with MPE...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4937920/ https://www.ncbi.nlm.nih.gov/pubmed/27368006 http://dx.doi.org/10.1097/MD.0000000000003996 |
_version_ | 1782441792432504832 |
---|---|
author | Verma, Akash Phua, Chee Kiang Sim, Wen Yuan Algoso, Reyes Elmer Tee, Kuan Sen Lew, Sennen J. W. Lim, Albert Y. H. Goh, Soon Keng Tai, Dessmon Y. H. Kor, Ai Ching Ho, Benjamin Abisheganaden, John |
author_facet | Verma, Akash Phua, Chee Kiang Sim, Wen Yuan Algoso, Reyes Elmer Tee, Kuan Sen Lew, Sennen J. W. Lim, Albert Y. H. Goh, Soon Keng Tai, Dessmon Y. H. Kor, Ai Ching Ho, Benjamin Abisheganaden, John |
author_sort | Verma, Akash |
collection | PubMed |
description | To study the performance of serum and pleural lactate dehydrogenase (LDH) level in predicting survival in patients with adenocarcinoma lung presenting with malignant pleural effusions (MPE) at initial diagnosis. Retrospective cohort study of the patient hospitalized for adenocarcinoma lung with MPE in year 2012. Univariate analyses showed lower pleural fluid LDH 667 (313–967) versus 971 (214–3800), P = 0.04, female gender 9 (100%) versus 27 (41.5%), P = 0.009, never smoking status 9 (100%) versus 36 (55.3%), P = 0.009, and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy 8 (89%) versus 26 (40%), P = 0.009 to correlate with survival of more than 1.7 year versus less than 1.7 year. In multivariate analysis, low pleural fluid LDH and female gender maintained significance. The pleural LDH level of ≤1500 and >1500 U/L discriminated significantly (P = 0.009) between survival. High pleural LDH (>1500 IU/L) predicts shorter survival (less than a year) in patients with adenocarcinoma lung presenting with MPE at the time of initial diagnosis. This marker may be clinically applied for selecting therapeutic modality directed at prevention of reaccumulation of MPE. Patients with low pleural LDH may be considered suitable for measures that provide more sustained effect on prevention of reaccumulation such as chemical pleurodesis or tunneled pleural catheter. |
format | Online Article Text |
id | pubmed-4937920 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Wolters Kluwer Health |
record_format | MEDLINE/PubMed |
spelling | pubmed-49379202016-08-18 Pleural LDH as a prognostic marker in adenocarcinoma lung with malignant pleural effusion Verma, Akash Phua, Chee Kiang Sim, Wen Yuan Algoso, Reyes Elmer Tee, Kuan Sen Lew, Sennen J. W. Lim, Albert Y. H. Goh, Soon Keng Tai, Dessmon Y. H. Kor, Ai Ching Ho, Benjamin Abisheganaden, John Medicine (Baltimore) 6700 To study the performance of serum and pleural lactate dehydrogenase (LDH) level in predicting survival in patients with adenocarcinoma lung presenting with malignant pleural effusions (MPE) at initial diagnosis. Retrospective cohort study of the patient hospitalized for adenocarcinoma lung with MPE in year 2012. Univariate analyses showed lower pleural fluid LDH 667 (313–967) versus 971 (214–3800), P = 0.04, female gender 9 (100%) versus 27 (41.5%), P = 0.009, never smoking status 9 (100%) versus 36 (55.3%), P = 0.009, and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy 8 (89%) versus 26 (40%), P = 0.009 to correlate with survival of more than 1.7 year versus less than 1.7 year. In multivariate analysis, low pleural fluid LDH and female gender maintained significance. The pleural LDH level of ≤1500 and >1500 U/L discriminated significantly (P = 0.009) between survival. High pleural LDH (>1500 IU/L) predicts shorter survival (less than a year) in patients with adenocarcinoma lung presenting with MPE at the time of initial diagnosis. This marker may be clinically applied for selecting therapeutic modality directed at prevention of reaccumulation of MPE. Patients with low pleural LDH may be considered suitable for measures that provide more sustained effect on prevention of reaccumulation such as chemical pleurodesis or tunneled pleural catheter. Wolters Kluwer Health 2016-07-01 /pmc/articles/PMC4937920/ /pubmed/27368006 http://dx.doi.org/10.1097/MD.0000000000003996 Text en Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved. http://creativecommons.org/licenses/by-nc-nd/4.0 This is an open access article distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0, where it is permissible to download, share and reproduce the work in any medium, provided it is properly cited. The work cannot be changed in any way or used commercially. http://creativecommons.org/licenses/by-nc-nd/4.0 |
spellingShingle | 6700 Verma, Akash Phua, Chee Kiang Sim, Wen Yuan Algoso, Reyes Elmer Tee, Kuan Sen Lew, Sennen J. W. Lim, Albert Y. H. Goh, Soon Keng Tai, Dessmon Y. H. Kor, Ai Ching Ho, Benjamin Abisheganaden, John Pleural LDH as a prognostic marker in adenocarcinoma lung with malignant pleural effusion |
title | Pleural LDH as a prognostic marker in adenocarcinoma lung with malignant pleural effusion |
title_full | Pleural LDH as a prognostic marker in adenocarcinoma lung with malignant pleural effusion |
title_fullStr | Pleural LDH as a prognostic marker in adenocarcinoma lung with malignant pleural effusion |
title_full_unstemmed | Pleural LDH as a prognostic marker in adenocarcinoma lung with malignant pleural effusion |
title_short | Pleural LDH as a prognostic marker in adenocarcinoma lung with malignant pleural effusion |
title_sort | pleural ldh as a prognostic marker in adenocarcinoma lung with malignant pleural effusion |
topic | 6700 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4937920/ https://www.ncbi.nlm.nih.gov/pubmed/27368006 http://dx.doi.org/10.1097/MD.0000000000003996 |
work_keys_str_mv | AT vermaakash pleuralldhasaprognosticmarkerinadenocarcinomalungwithmalignantpleuraleffusion AT phuacheekiang pleuralldhasaprognosticmarkerinadenocarcinomalungwithmalignantpleuraleffusion AT simwenyuan pleuralldhasaprognosticmarkerinadenocarcinomalungwithmalignantpleuraleffusion AT algosoreyeselmer pleuralldhasaprognosticmarkerinadenocarcinomalungwithmalignantpleuraleffusion AT teekuansen pleuralldhasaprognosticmarkerinadenocarcinomalungwithmalignantpleuraleffusion AT lewsennenjw pleuralldhasaprognosticmarkerinadenocarcinomalungwithmalignantpleuraleffusion AT limalbertyh pleuralldhasaprognosticmarkerinadenocarcinomalungwithmalignantpleuraleffusion AT gohsoonkeng pleuralldhasaprognosticmarkerinadenocarcinomalungwithmalignantpleuraleffusion AT taidessmonyh pleuralldhasaprognosticmarkerinadenocarcinomalungwithmalignantpleuraleffusion AT koraiching pleuralldhasaprognosticmarkerinadenocarcinomalungwithmalignantpleuraleffusion AT hobenjamin pleuralldhasaprognosticmarkerinadenocarcinomalungwithmalignantpleuraleffusion AT abisheganadenjohn pleuralldhasaprognosticmarkerinadenocarcinomalungwithmalignantpleuraleffusion |